Abstract: The present invention provides a crystalline 2,4-bridged common intermediate useful for producing a plurality of ENA monomers, a method for stereoselectively producing the intermediate, and a method for efficiently producing ENA monomers using the intermediate.

Abstract: It is an object of the present invention to provide an excellent method for producing an excellent therapeutic agent. The solution of the present invention is as shown in the following scheme: wherein R1 represents a C1-C6 alkyl group, R2 represents a C1-C6 alkyl group, and R3 represents a C1-C6 alkyl group.

Abstract: It is an object of the present invention to provide an excellent method for producing an excellent therapeutic agent. The solution of the present invention is as shown in the following scheme: wherein R1 represents a C1-C6 alkyl group, R2 represents a C1-C6 alkyl group, and R3 represents a C1-C6 alkyl group.

Abstract: The problem to be solved is to provide a method for efficiently producing compounds (1) and (1a) that are important intermediate compounds in the production of FXa inhibitors (X) and (X-a). The solutions thereto are a method for producing a compound represented by the formula (8d) using a stereoselective intramolecular cyclization reaction, and a method for producing a compound (1f) or a salt thereof, or a hydrate thereof, which is characterized by desulfonylation of the compound (8d). In each formula, R4a represents a C1-C6 alkyl group, a benzyl group, etc.

Abstract: It is an object of the present invention to provide a method for producing a high-purity tricyclic heterocyclic compound represented by formula (I), which is useful as a production intermediate for a pharmaceutical agent, wherein the method is an efficient production method with short steps and with a high yield, which does not use, as raw materials, expensive bromopyruvate and highly harmful copper chromite, and does not need silica gel column chromatography that generates, as by-products, large quantities of waste. The present invention relates to production of Compound (I) by the following method.

Abstract: The problem to be solved is to provide a method for efficiently producing compounds (1) and (1a) that are important intermediate compounds in the production of FXa inhibitors (X) and (X-a). The solutions thereto are a method for producing a compound represented by the formula (8d) using a stereoselective intramolecular cyclization reaction, and a method for producing a compound (1f) or a salt thereof, or a hydrate thereof, which is characterized by desulfonylation of the compound (8d). In each formula, R4a represents a C1-C6 alkyl group, a benzyl group, etc.

Abstract: A 1-methylcarbapenem compound ethanolate of the formula (I-1) in the crystalline form that shows main peaks at interplanar spacings d=7.60, 6.69, 6.33, 6.14, 5.15, 4.58 and 4.48 in the X-ray powder diffraction pattern obtained with Cu K? irradiation and a 1-methylcarbapenem compound tetrahydrate of the formula (I-2) in the crystalline form that shows main peaks at interplanar spacings d=11.68, 8.79, 7.53, 6.57, 5.58, 5.37, 3.99 and 3.09 in the X-ray powder diffraction pattern obtained with Cu K? irradiation These compounds are useful for treating or preventing bacterial infections.

Abstract: Among crystalline forms of compound (I), a 1-methylcarbapenem compound represented by the formula (I) in a crystalline form that shows main peaks in the X-ray powder diffraction pattern obtained with copper K? irradiation.

Abstract: A process for the preparation of carbapenem-type antibacterial agents involving the following reaction: wherein R1 is a C1-C3 alkyl group, n is 0, 1 or 2, A is a C1-C3 alkylene group, L is a leaving group, R3 is a hydrogen atom, a C1-C3 alkyl group or an amino protecting group, and the hydroxyl or carboxyl groups are optionally independently protected. In such process, amine compound (1) or a salt thereof acts as a synthetic intermediate. Such process is a less expensive and highly safe synthetic route for carbapenem-type antibacterial agents suitable for large-scale synthesis.

Abstract: A 1-methylcarbapenem compound ethanolate of the formula (I-1) in the crystalline form that shows main peaks at interplanar spacings d=7.60, 6.69, 6.33, 6.14, 5.15, 4.58 and 4.48 in the X-ray powder diffraction pattern obtained with Cu K? irradiation and a 1-methylcarbapenem compound tetrahydrate of the formula (I-2) in the crystalline form that shows main peaks at interplanar spacings d=11.68, 8.79, 7.53, 6.57, 5.58, 5.37, 3.99 and 3.09 in the X-ray powder diffraction pattern obtained with Cu K? irradiation These compounds are useful for treating or preventing bacterial infections.